Anti-CD23

被引:68
作者
Rosenwasser, LJ [1 ]
Meng, JF
机构
[1] Univ Colorado, Div Allergy & Immunol, Dept Med,Hlth Sci Ctr, Natl Jewish Med & Res Ctr, Denver, CO 80202 USA
[2] Natl Jewish Med & Res Ctr, Dept Med, Div Allergy & Immunol, Denver, CO USA
关键词
IgE; IgE low affinity receptor (CD23); anti-CD23; allergic diseases;
D O I
10.1385/CRIAI:29:1:061
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
CD23, the low-affinity immunoglobulin (Ig)E receptor (Fc epsilon RII), is widely distributed on the surface of various human cells. CD23 mediates numerous IgE-related immune responses (including allergen focusing) by enhancing IgE antigen complex presentation, regulating IgE synthesis, influencing cell differentiation and growth of both B- and T-cells, and stimulating production of pro-inflammatory mediators from monocytes/macrophages, eosinophils, and even airway smooth muscle cells. Both membrane and soluble CD23 play an important role in allergic reactions. Cellular contacts and cytokines modulate its expression in a concerted manner as needed for allergic reactions. Expression of CD23 and soluble CD23 has been associated with allergic diseases. Targeting CD23 with monoclonal antibody (MAb) is a promising candidate therapy in allergic diseases. A newly developed agent known as Lumiliximab, which is an anti-CD23 MAb (Lumiliximab), was demonstrated to be a well-tolerated agent in a phase I clinical trial (a placebo-controlled study with allergic asthma). Adverse events were mild, and no relationship was apparent between the dose of Lumilixilab and the frequency, severity, or type of event. Sustained and dose-dependent decreases in mean serum total IgE concentrations were noted. The serum half-life of Lumilixilab increased from 2 to 10 d with increasing doses. Blocking antigen presentation, preventing costimulation signals, and reducing production of pro-inflammatory mediators are some of the potential mechanisms involved for anti-CD23 activity. Although the safety and clinical efficacy of Lumilixilab in allergic asthma and rhinitis require confirmation, the observed data imply that anti-CD23 is a promising candidate therapy option for future treatment of allergic diseases.
引用
收藏
页码:61 / 72
页数:12
相关论文
共 127 条
  • [1] Molecular characterization of the low-affinity IgE receptor FcεRII/CD23 expressed by human eosinophils
    Abdelilah, SG
    Bouchaïb, L
    Morita, M
    Delphine, A
    Marika, S
    André, C
    Monique, C
    [J]. INTERNATIONAL IMMUNOLOGY, 1998, 10 (04) : 395 - 404
  • [2] REGULATION OF CYTOKINE PRODUCTION BY SOLUBLE CD23 - COSTIMULATION OF INTERFERON-GAMMA SECRETION AND TRIGGERING OF TUMOR-NECROSIS-FACTOR-ALPHA RELEASE
    ARMANT, M
    ISHIHARA, H
    RUBIO, M
    DELESPESSE, G
    SARFATI, M
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 180 (03) : 1005 - 1011
  • [3] INVOLVEMENT OF FC-EPSILON-RII/CD23 AND L-ARGININE DEPENDENT PATHWAY IN IGE-MEDIATED ACTIVATION OF HUMAN EOSINOPHILS
    AROCK, M
    LEGOFF, L
    BECHEREL, PA
    DUGAS, B
    DEBRE, P
    MOSSALAYI, MD
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1994, 203 (01) : 265 - 271
  • [4] A MULTIPARAMETER FLOW CYTOMETRIC METHOD TO STUDY SURFACE MOLECULES INVOLVED IN INTERACTIONS BETWEEN SUBPOPULATIONS OF CELLS
    AUBRY, JP
    SHIELDS, JG
    JANSEN, KU
    BONNEFOY, JY
    [J]. JOURNAL OF IMMUNOLOGICAL METHODS, 1993, 159 (1-2) : 161 - 171
  • [5] CD21 IS A LIGAND FOR CD23 AND REGULATES IGE PRODUCTION
    AUBRY, JP
    POCHON, S
    GRABER, P
    JANSEN, KU
    BONNEFOY, JY
    [J]. NATURE, 1992, 358 (6386) : 505 - 507
  • [6] Inducible nitric oxide synthase and proinflammatory cytokine expression by human keratinocytes during acute urticaria
    Becherel, PA
    Chosidow, O
    LeGoff, L
    Frances, C
    Debre, P
    Mossalayi, MD
    Arock, M
    [J]. MOLECULAR MEDICINE, 1997, 3 (10) : 686 - 694
  • [7] INDUCTION OF FC-EPSILON-R2/CD23 ON HUMAN EPIDERMAL LANGERHANS CELLS BY HUMAN RECOMBINANT INTERLEUKIN-4 AND GAMMA-INTERFERON
    BIEBER, T
    RIEGER, A
    NEUCHRIST, C
    PRINZ, JC
    RIEBER, EP
    BOLTZNITULESCU, G
    SCHEINER, O
    KRAFT, D
    RING, J
    STINGL, G
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1989, 170 (01) : 309 - 314
  • [8] GAMMA-INTERFERON PROMOTES THE RELEASE OF IGE-BINDING FACTORS (SOLUBLE CD23) BY HUMAN EPIDERMAL LANGERHANS CELLS
    BIEBER, T
    DELESPESSE, G
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1991, 97 (03) : 600 - 603
  • [9] BOLTZNITULESCU G, 1988, IMMUNOLOGY, V63, P529
  • [10] BONNEFOY JY, 1993, EUR J IMMUNOL, V23, P969